Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.
about
FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myelomaThe cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of ImmunotherapySuppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role.Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance.Immunologic microenvironment and personalized treatment in multiple myeloma.Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice.Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myelomaTargeting the bone marrow microenvironment in multiple myeloma.Personalization of cancer treatment using predictive simulationTargeting the Bone Marrow Microenvironment.Is immunotherapy here to stay in multiple myeloma?Standardisation of minimal residual disease in multiple myeloma.Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma.The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma.Monitoring NK cell activity in patients with hematological malignancies.A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.Bone marrow microenvironmental CD4 + and CD8 + lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma--an analysis from the Austrian Myeloma Registry.Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The AusElotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.
P2860
Q34402407-13745FCC-746C-4B06-8D98-706596FFDFFEQ34773850-2632B503-9A57-498C-8E9E-E8765824E055Q35648024-C0FDB19B-8EFE-48BA-ACB5-40842108F445Q35669068-D4ADF837-176E-46A8-A382-10686335B419Q36416269-837A5025-235D-4E6B-B7F4-60B5CF0F3BB5Q36436758-8BC8F29E-8D11-430E-9523-AD228DDB7658Q36799760-076DA38A-B82A-43BB-B62E-933702CDA711Q37132264-A00205BC-9CDA-4AC5-BCC2-2BD0643E22CBQ37212043-0F7EE603-991A-46C6-A6D1-82C9C60CCBD6Q38108390-F78AEDD6-E01C-4CE7-A195-462389C6E261Q38165722-B8021133-AE23-47F0-929C-5275B93F84ACQ38219408-A457D69A-0FF3-4D72-A1C0-45C4C1C4CB49Q38289041-82DD9281-CDFD-4154-B37A-75C427CCA083Q38914605-B846892B-BA29-4C0C-AB29-7F12D0680041Q38970585-2A9465FF-8BB8-48BE-86CA-492A9682F6B0Q39084427-D88A1E1F-D0A8-44E3-81D5-DD9AFDFF02B8Q39410899-90B98037-9376-476D-8849-39B54D5DBCE9Q39901834-607C45C5-4988-46D8-B727-66B6EAFA311FQ40178024-2D30220D-F5ED-46BF-8060-385AE125F4F0Q42847576-F04DC2DF-A810-449C-82DA-BDC93E2369A9Q47865755-42BCF9BC-08F2-4081-9D6E-BF856C5F5EE7Q48188365-C85C936B-6DBC-4A57-A2FC-7605BB16722AQ50589659-41F9296B-8C09-4F45-8E63-028F655A7B44Q52913745-BADA93DE-C445-4C74-B627-5150FAA4381DQ53797232-D8B7FDC8-BC45-4CC7-8D6E-D33629319961Q55310350-E7AA0847-5853-41BE-B5E8-D1732907C7DE
P2860
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Analysis of the immune system ...... ltidimensional flow cytometry.
@ast
Analysis of the immune system ...... ltidimensional flow cytometry.
@en
type
label
Analysis of the immune system ...... ltidimensional flow cytometry.
@ast
Analysis of the immune system ...... ltidimensional flow cytometry.
@en
prefLabel
Analysis of the immune system ...... ltidimensional flow cytometry.
@ast
Analysis of the immune system ...... ltidimensional flow cytometry.
@en
P2093
P2860
P50
P1433
P1476
Analysis of the immune system ...... ultidimensional flow cytometry
@en
P2093
Alberto Orfao
Angelo Maiolino
Bruno Paiva
Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups
Jose Hernández
Juan F Blanco
Juan-Jose Lahuerta
Maria-Victoria Mateos
Monica Roig
Quentin Lecrevisse
P2860
P356
10.3324/HAEMATOL.2012.067272
P50
P577
2012-07-06T00:00:00Z